Accelerated access to innovative medicines for patients in need

L. G. Baird, R. Banken, H. G. Eichler, F. B. Kristensen, D. K. Lee, J. C W Lim, R. Lim, C. Longson, E. Pezalla, T. Salmonson, D. Samaha, S. Tunis, J. Woodcock, G. Hirsch

Research output: Contribution to journalArticle

Abstract

There is broad agreement among health-care stakeholders that more must be done to ensure that patients have timely access to new and innovative medicines. Assuming that industry will continue to develop such medicines at a sustainable rate, regulators and payers become the gatekeepers. Regulators, starting in the late 1980s/early 1990s, and, more recently, payers have implemented a variety of early-access pathways or initiatives, and this practice is continuing even today. This article describes the specific approaches that have been taken in four economically developed regions, reviews their success rates, and suggests possible new directions.

Original languageEnglish (US)
Pages (from-to)559-571
Number of pages13
JournalClinical Pharmacology and Therapeutics
Volume96
Issue number5
DOIs
StatePublished - Aug 13 2014
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Fingerprint Dive into the research topics of 'Accelerated access to innovative medicines for patients in need'. Together they form a unique fingerprint.

  • Cite this

    Baird, L. G., Banken, R., Eichler, H. G., Kristensen, F. B., Lee, D. K., Lim, J. C. W., Lim, R., Longson, C., Pezalla, E., Salmonson, T., Samaha, D., Tunis, S., Woodcock, J., & Hirsch, G. (2014). Accelerated access to innovative medicines for patients in need. Clinical Pharmacology and Therapeutics, 96(5), 559-571. https://doi.org/10.1038/clpt.2014.145